Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Protein Tyrosine Phosphatase, Non-Receptor Type 11"" wg kryterium: Temat


Tytuł :
Grass carp (Ctenopharyngodon idellus) SHP2 suppresses IFN I expression via decreasing the phosphorylation of GSK3β in a non-contact manner.
Autorzy :
Lu S; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China.
Peng X; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China.
Lin G; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China.
Xu K; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China.
Wang S; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China.
Qiu W; Teaching Material Research Office of Jiangxi Provincial Education Department, Nanchang, 330046, Jiangxi, China.
Du H; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China.
Chang K; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China.
Lv Y; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China.
Liu Y; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China.
Deng H; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China.
Hu C; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China.
Xu X; School of Life Science, Nanchang University, Nanchang, 330031, Jiangxi, China. Electronic address: .
Pokaż więcej
Źródło :
Fish & shellfish immunology [Fish Shellfish Immunol] 2021 Sep; Vol. 116, pp. 150-160. Date of Electronic Publication: 2021 Jul 12.
Typ publikacji :
Journal Article
MeSH Terms :
Carps/*immunology
Fish Proteins/*immunology
Glycogen Synthase Kinase 3 beta/*immunology
Interferon Type I/*immunology
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*immunology
Amino Acid Sequence ; Animals ; Carps/genetics ; Cell Line ; Fish Proteins/genetics ; Phosphorylation ; Phylogeny ; Poly I-C/pharmacology ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics
Czasopismo naukowe
Tytuł :
Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth.
Autorzy :
Wang Y; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Salvucci O; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ohnuki H; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Tran AD; Center for Cancer Research Microscopy Core, Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ha T; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Feng JX; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
DiPrima M; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kwak H; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Wang D; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Yu Y; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kruhlak M; Center for Cancer Research Microscopy Core, Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Tosato G; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Pokaż więcej
Źródło :
EMBO molecular medicine [EMBO Mol Med] 2021 Jul 07; Vol. 13 (7), pp. e14089. Date of Electronic Publication: 2021 Jun 08.
Typ publikacji :
Journal Article; Research Support, N.I.H., Intramural
MeSH Terms :
Neoplasms*/drug therapy
Protein Tyrosine Phosphatase, Non-Receptor Type 11*/metabolism
Animals ; Endothelial Cells/metabolism ; Mice ; Receptor Protein-Tyrosine Kinases ; Signal Transduction
Czasopismo naukowe
Tytuł :
Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
Autorzy :
Yang X; Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing, 100049, China.
Wang Z; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; School of Pharmaceutical Science, Jiangnan University, Wuxi, 214122, China.
Pei Y; Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing, 100049, China.
Song N; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing, 100049, China; ShanghaiTech University, 393 Middle Huaxia Road, Shanghai, 201210, China.
Xu L; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Feng B; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, No.103 Wenhua Road, Shenyang, Liaoning, China.
Wang H; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; School of Pharmacy, Fudan University, Shanghai, 201203, China.
Luo X; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210046, China.
Hu X; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Qiu X; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Feng H; Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Yang Y; Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing, 100049, China; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China.
Zhou Y; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing, 100049, China. Electronic address: .
Li J; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing, 100049, China; ShanghaiTech University, 393 Middle Huaxia Road, Shanghai, 201210, China; School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, No.103 Wenhua Road, Shenyang, Liaoning, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210046, China. Electronic address: .
Zhou B; Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing, 100049, China; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Jun 05; Vol. 218, pp. 113341. Date of Electronic Publication: 2021 Mar 11.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Discovery*
Antineoplastic Agents/*pharmacology
Enzyme Inhibitors/*pharmacology
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*antagonists & inhibitors
Small Molecule Libraries/*pharmacology
Thalidomide/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Enzyme Inhibitors/chemical synthesis ; Enzyme Inhibitors/chemistry ; Humans ; Molecular Structure ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism ; Small Molecule Libraries/chemical synthesis ; Small Molecule Libraries/chemistry ; Structure-Activity Relationship ; Thalidomide/chemical synthesis ; Thalidomide/chemistry ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Determination of the molecular reach of the protein tyrosine phosphatase SHP-1.
Autorzy :
Clemens L; Center for Complex Biological Systems, University of California Irvine, Irvine, California.
Kutuzov M; Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Bayer KV; Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Goyette J; EMBL Australia Node in Single Molecule Science, School of Medical Sciences University of New South Wales, Sydney, Australia; ARC Centre of Excellence in Advanced Molecular Imaging, University of New South Wales, Sydney, Australia.
Allard J; Center for Complex Biological Systems, University of California Irvine, Irvine, California. Electronic address: .
Dushek O; Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom. Electronic address: .
Pokaż więcej
Źródło :
Biophysical journal [Biophys J] 2021 May 18; Vol. 120 (10), pp. 2054-2066. Date of Electronic Publication: 2021 Mar 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Protein Tyrosine Phosphatase, Non-Receptor Type 11*
Tyrosine*/metabolism
Phosphorylation ; Protein Phosphatase 1 ; Protein Tyrosine Phosphatase, Non-Receptor Type 6/metabolism ; SH2 Domain-Containing Protein Tyrosine Phosphatases
Czasopismo naukowe
Tytuł :
PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment.
Autorzy :
Takehara T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.; Department of Immunology, Tokyo Medical University, Tokyo, Japan.
Wakamatsu E; Department of Immunology, Tokyo Medical University, Tokyo, Japan.
Machiyama H; Department of Immunology, Tokyo Medical University, Tokyo, Japan.
Nishi W; Department of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Emoto K; Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
Azuma M; Department of Molecular Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Soejima K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Fukunaga K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Yokosuka T; Department of Immunology, Tokyo Medical University, Tokyo, Japan. .
Pokaż więcej
Źródło :
Communications biology [Commun Biol] 2021 May 14; Vol. 4 (1), pp. 581. Date of Electronic Publication: 2021 May 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CD8-Positive T-Lymphocytes/*immunology
Dendritic Cells/*immunology
Lymphocyte Activation/*immunology
Programmed Cell Death 1 Ligand 2 Protein/*metabolism
Programmed Cell Death 1 Receptor/*physiology
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*metabolism
Animals ; CD8-Positive T-Lymphocytes/metabolism ; Cells, Cultured ; Dendritic Cells/metabolism ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Programmed Cell Death 1 Ligand 2 Protein/genetics ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics ; Signal Transduction
Czasopismo naukowe
Tytuł :
Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.
Autorzy :
Day EK; Department of Chemical Engineering, University of Virginia, Charlottesville, Virginia.; Department of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, Pennsylvania.
Zhong Q; Department of Neurology, University of Virginia, Charlottesville, Virginia.
Purow B; Department of Neurology, University of Virginia, Charlottesville, Virginia.
Lazzara MJ; Department of Chemical Engineering, University of Virginia, Charlottesville, Virginia. .; Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia.
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2021 Apr 15; Vol. 81 (8), pp. 2056-2070. Date of Electronic Publication: 2021 Feb 11.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Brain Neoplasms/*drug therapy
Glioblastoma/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*antagonists & inhibitors
Animals ; Brain Neoplasms/enzymology ; Cell Line, Tumor ; DNA Repair/physiology ; Data Science ; Dimethyl Sulfoxide/therapeutic use ; Drug Resistance, Neoplasm ; Female ; Gefitinib/therapeutic use ; Glioblastoma/enzymology ; Heterografts ; Humans ; Indoles/therapeutic use ; Intracellular Signaling Peptides and Proteins/metabolism ; Least-Squares Analysis ; MAP Kinase Signaling System ; Mice ; Mice, Inbred BALB C ; Mice, SCID ; Models, Biological ; Neoplasm Transplantation ; PTEN Phosphohydrolase/metabolism ; Phenotype ; Phosphorylation ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Signal Transduction ; Sulfones/therapeutic use ; Temozolomide/therapeutic use ; Transcription Factor AP-1/metabolism ; src Homology Domains
Czasopismo naukowe
Tytuł :
Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2 by molecular dynamics study.
Autorzy :
Zhou L; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Feng Y; Department of Otorhinolaryngology Head and Neck, The 4th Central Hospital of Tianjin, Tianjin, China.
Ma YC; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Zhang Z; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China; Tianjin First Central Hospital, No. 24, Fukang Road, Nankai District, Tianjin, China.
Wu JW; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Du S; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Li WY; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Lu XH; New Drug Research & Development Center of North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering & Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Key Laboratory for New Drug Screening Technology of Shijiazhuang City, Shijiazhuang, 050015, Hebei, China.
Ma Y; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China. Electronic address: .
Wang RL; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China. Electronic address: .
Pokaż więcej
Źródło :
Journal of molecular graphics & modelling [J Mol Graph Model] 2021 Mar; Vol. 103, pp. 107807. Date of Electronic Publication: 2020 Dec 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Molecular Dynamics Simulation*
Protein Tyrosine Phosphatase, Non-Receptor Type 11*/genetics
Protein Tyrosine Phosphatase, Non-Receptor Type 11*/metabolism
Molecular Conformation ; Molecular Docking Simulation ; Mutation
Czasopismo naukowe
Tytuł :
Grb2 binding induces phosphorylation-independent activation of Shp2.
Autorzy :
Lin CC; School of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK. .
Wieteska L; School of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK.
Suen KM; School of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK.; Wellcome Trust Cancer Research UK Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge, UK.
Kalverda AP; School of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK.
Ahmed Z; Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ladbury JE; School of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK. .; Department of Chemistry, Indian Institute of Technology Bombay, Mumbai, India. .
Pokaż więcej
Źródło :
Communications biology [Commun Biol] 2021 Apr 01; Vol. 4 (1), pp. 437. Date of Electronic Publication: 2021 Apr 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Signal Transduction*
GRB2 Adaptor Protein/*genetics
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*genetics
Enzyme Activation ; GRB2 Adaptor Protein/metabolism ; Phosphorylation ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism
Czasopismo naukowe
Tytuł :
Targeting SHP2 as a therapeutic strategy for inflammatory diseases.
Autorzy :
Liu Y; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Yang X; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Wang Y; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Yang Y; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Sun D; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: .
Li H; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China; Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Electronic address: .
Chen L; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Mar 15; Vol. 214, pp. 113264. Date of Electronic Publication: 2021 Feb 06.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Biological Products/*therapeutic use
Enzyme Inhibitors/*therapeutic use
Inflammation/*drug therapy
Metabolic Diseases/*drug therapy
Neurodegenerative Diseases/*drug therapy
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*antagonists & inhibitors
Biological Products/chemistry ; Enzyme Inhibitors/chemistry ; Humans ; Inflammation/metabolism ; Metabolic Diseases/metabolism ; Molecular Structure ; Neurodegenerative Diseases/metabolism ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism
Czasopismo naukowe
Tytuł :
Emerging chemical scaffolds with potential SHP2 phosphatase inhibitory capabilities - A comprehensive review.
Autorzy :
Tripathi RKP; Department of Pharmaceutical Science, Sushruta School of Medical and Paramedical Sciences, Assam University (A Central University), Silchar, Assam, India.; Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Ayyannan SR; Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Pokaż więcej
Źródło :
Chemical biology & drug design [Chem Biol Drug Des] 2021 Mar; Vol. 97 (3), pp. 721-773. Date of Electronic Publication: 2020 Nov 27.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Enzyme Inhibitors/*chemistry
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*metabolism
Allosteric Site ; Apoptosis/drug effects ; Cytokines/metabolism ; Enzyme Inhibitors/metabolism ; Enzyme Inhibitors/pharmacology ; Humans ; Molecular Docking Simulation ; Neoplasms/metabolism ; Neoplasms/pathology ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/antagonists & inhibitors ; Signal Transduction/drug effects ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Protein Tyrosine Phosphatase SHP2 Suppresses Host Innate Immunity against Influenza A Virus by Regulating EGFR-Mediated Signaling.
Autorzy :
Wang Q; Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, China.
Pan W; Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, China.
Wang S; Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, China.
Pan C; Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, China.
Ning H; Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, China.
Huang S; Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.; Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
Chiu SH; Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, China .
Chen JL; Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, China .; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Pokaż więcej
Źródło :
Journal of virology [J Virol] 2021 Feb 24; Vol. 95 (6). Date of Electronic Publication: 2021 Feb 24 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunity, Innate*
ErbB Receptors/*metabolism
Influenza A virus/*physiology
Orthomyxoviridae Infections/*immunology
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*immunology
A549 Cells ; Animals ; ErbB Receptors/antagonists & inhibitors ; Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors ; Extracellular Signal-Regulated MAP Kinases/metabolism ; Humans ; Immune Evasion ; Interferons/metabolism ; Mice ; Orthomyxoviridae Infections/virology ; Phosphorylation ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics ; Signal Transduction/immunology ; Virus Replication
Czasopismo naukowe
Tytuł :
Exploring the Distinct Binding and Activation Mechanisms for Different CagA Oncoproteins and SHP2 by Molecular Dynamics Simulations.
Autorzy :
Wang Q; Edmond H. Fischer Signal Transduction Laboratory, College of Life Sciences, Jilin University, Changchun 130023, China.
Zhao WC; Edmond H. Fischer Signal Transduction Laboratory, College of Life Sciences, Jilin University, Changchun 130023, China.
Fu XQ; Edmond H. Fischer Signal Transduction Laboratory, College of Life Sciences, Jilin University, Changchun 130023, China.
Zheng QC; Laboratory of Theoretical and Computational Chemistry, Institute of Theoretical Chemistry, International Joint Research Laboratory of Nano-Micro Architecture Chemistry, Jilin University, Changchun 130023, China.
Pokaż więcej
Źródło :
Molecules (Basel, Switzerland) [Molecules] 2021 Feb 05; Vol. 26 (4). Date of Electronic Publication: 2021 Feb 05.
Typ publikacji :
Journal Article
MeSH Terms :
Molecular Dynamics Simulation*
Antigens, Bacterial/*metabolism
Bacterial Proteins/*metabolism
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*metabolism
Allosteric Regulation ; Antigens, Bacterial/chemistry ; Bacterial Proteins/chemistry ; Enzyme Activation ; Hydrogen Bonding ; Molecular Docking Simulation ; Protein Binding ; Protein Conformation ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/chemistry ; Thermodynamics
Czasopismo naukowe
Tytuł :
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling.
Autorzy :
Fedele C; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Li S; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Teng KW; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Foster CJR; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Peng D; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Ran H; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Mita P; Institute for Systems Genetics and Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, NYU Langone Health, New York, NY.
Geer MJ; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Hattori T; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, NYU Langone Health, New York, NY.
Koide A; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.; Department of Medicine, New York University School of Medicine, NYU Langone Health, New York, NY.
Wang Y; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Tang KH; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Leinwand J; S. Arthur Localio Laboratory, Department of Surgery, New York University School of Medicine, NYU Langone Health, New York, NY.
Wang W; S. Arthur Localio Laboratory, Department of Surgery, New York University School of Medicine, NYU Langone Health, New York, NY.
Diskin B; S. Arthur Localio Laboratory, Department of Surgery, New York University School of Medicine, NYU Langone Health, New York, NY.
Deng J; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Chen T; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Dolgalev I; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Ozerdem U; Department of Pathology, New York University School of Medicine, NYU Langone Health, New York, NY.
Miller G; S. Arthur Localio Laboratory, Department of Surgery, New York University School of Medicine, NYU Langone Health, New York, NY.
Koide S; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, NYU Langone Health, New York, NY.
Wong KK; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Neel BG; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, NY.
Pokaż więcej
Źródło :
The Journal of experimental medicine [J Exp Med] 2021 Jan 04; Vol. 218 (1).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Mutation, Missense*
Carcinoma, Non-Small-Cell Lung/*immunology
Carcinoma, Pancreatic Ductal/*immunology
Enzyme Inhibitors/*pharmacology
Lung Neoplasms/*immunology
Pancreatic Neoplasms/*immunology
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*antagonists & inhibitors
Proto-Oncogene Proteins p21(ras)/*immunology
Tumor Microenvironment/*drug effects
Amino Acid Substitution ; Animals ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Pancreatic Ductal/drug therapy ; Carcinoma, Pancreatic Ductal/genetics ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Mice ; Mice, Knockout ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/genetics ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/immunology ; Proto-Oncogene Proteins p21(ras)/genetics ; Tumor Microenvironment/genetics ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).
Autorzy :
Wu J; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, No. 22, Qixiangtai Road, Heping District, Tianjin 300070, China.
Zhang H; Department of Pharmacy, Tianjin Medical University General Hospital, Tianjin 300052, China.
Zhao G; The Institute of Drug Discovery and Development, Chinese Academy of Sciences, Zhongshan 528400, China.
Wang R; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, No. 22, Qixiangtai Road, Heping District, Tianjin 300070, China.
Pokaż więcej
Źródło :
Current medicinal chemistry [Curr Med Chem] 2021; Vol. 28 (19), pp. 3825-3842.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Neoplasms*
Protein Tyrosine Phosphatase, Non-Receptor Type 11*/genetics
Protein Tyrosine Phosphatase, Non-Receptor Type 11*/metabolism
Allosteric Site ; Enzyme Inhibitors ; Humans ; Mutation
Czasopismo naukowe
Tytuł :
A novel partially open state of SHP2 points to a "multiple gear" regulation mechanism.
Autorzy :
Tao Y; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China.
Xie J; Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China; University of the Chinese Academy of Sciences, Beijing, China.
Zhong Q; University of the Chinese Academy of Sciences, Beijing, China; Laboratory of Molecular Modeling and Design, State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
Wang Y; Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China; Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Zhang S; Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China; University of the Chinese Academy of Sciences, Beijing, China.
Luo F; Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China; University of the Chinese Academy of Sciences, Beijing, China.
Wen F; School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Xie J; Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China; University of the Chinese Academy of Sciences, Beijing, China.
Zhao J; Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing, China.
Sun X; Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing, China.
Long H; Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China; University of the Chinese Academy of Sciences, Beijing, China.
Ma J; Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing, China.
Zhang Q; School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Long J; Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China.
Fang X; Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing, China.
Lu Y; University of the Chinese Academy of Sciences, Beijing, China; Beijing National Laboratory for Condensed Matter Physics and CAS Key Laboratory of Soft Matter Physics, Institute of Physics, Chinese Academy of Sciences, Beijing, China.
Li D; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China.
Li M; University of the Chinese Academy of Sciences, Beijing, China; Beijing National Laboratory for Condensed Matter Physics and CAS Key Laboratory of Soft Matter Physics, Institute of Physics, Chinese Academy of Sciences, Beijing, China.
Zhu J; Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China; University of the Chinese Academy of Sciences, Beijing, China.
Sun B; School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Li G; University of the Chinese Academy of Sciences, Beijing, China; Laboratory of Molecular Modeling and Design, State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China. Electronic address: .
Diao J; Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Electronic address: .
Liu C; Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China; University of the Chinese Academy of Sciences, Beijing, China. Electronic address: .
Pokaż więcej
Źródło :
The Journal of biological chemistry [J Biol Chem] 2021 Jan-Jun; Vol. 296, pp. 100538. Date of Electronic Publication: 2021 Mar 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Calgranulin A/*metabolism
Insulin Receptor Substrate Proteins/*metabolism
Piperidines/*metabolism
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*chemistry
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*metabolism
Pyrimidines/*metabolism
Allosteric Regulation ; Humans ; Molecular Dynamics Simulation ; Mutation ; Protein Binding ; Protein Conformation ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics
Czasopismo naukowe
Tytuł :
From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.
Autorzy :
Mostinski Y; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Heynen GJJE; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
López-Alberca MP; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Paul J; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Miksche S; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Radetzki S; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Schaller D; Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Shanina E; Max-Planck-Institut für Kolloid- und Grenzflächenforschung, Am Mühlenberg, 1, 14476 Potsdam, Germany.
Seyffarth C; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Kolomeets Y; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Ziebart N; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
de Schryver J; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Oestreich S; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Neuenschwander M; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Roske Y; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Heinemann U; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Rademacher C; Max-Planck-Institut für Kolloid- und Grenzflächenforschung, Am Mühlenberg, 1, 14476 Potsdam, Germany.
Volkamer A; Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
von Kries JP; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Birchmeier W; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Nazaré M; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Dec 10; Vol. 63 (23), pp. 14780-14804. Date of Electronic Publication: 2020 Nov 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Enzyme Inhibitors/*pharmacology
Indoles/*pharmacology
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*antagonists & inhibitors
Pyrazolones/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/metabolism ; Antineoplastic Agents/pharmacology ; Catalytic Domain ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Screening Assays, Antitumor ; Enzyme Inhibitors/chemical synthesis ; Enzyme Inhibitors/metabolism ; Humans ; Indoles/chemical synthesis ; Indoles/metabolism ; MAP Kinase Signaling System/drug effects ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Molecular Structure ; Protein Binding ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/chemistry ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism ; Pyrazolones/chemical synthesis ; Pyrazolones/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
Autorzy :
Wang J; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Pollard K; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Allen AN; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Tomar T; PamGene International BV, 's-Hertogenbosch, the Netherlands.
Pijnenburg D; PamGene International BV, 's-Hertogenbosch, the Netherlands.
Yao Z; Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Rodriguez FJ; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Pratilas CA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2020 Dec 01; Vol. 80 (23), pp. 5367-5379. Date of Electronic Publication: 2020 Oct 08.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Mitogen-Activated Protein Kinase Kinases/*antagonists & inhibitors
Nerve Sheath Neoplasms/*drug therapy
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*antagonists & inhibitors
Animals ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Resistance, Neoplasm ; Drug Screening Assays, Antitumor ; Humans ; Mice, Nude ; Mitogen-Activated Protein Kinase Kinases/metabolism ; Nerve Sheath Neoplasms/metabolism ; Neurofibroma/drug therapy ; Neurofibroma/pathology ; Neurofibromin 1/genetics ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism ; Pyridones/administration & dosage ; Pyridones/pharmacology ; Pyrimidinones/administration & dosage ; Pyrimidinones/pharmacology ; Small Molecule Libraries/pharmacology ; Xenograft Model Antitumor Assays ; ras Proteins/metabolism
Czasopismo naukowe
Tytuł :
Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds.
Autorzy :
Guo W; State Key Laboratory of Pharmaceutical Biotechnology and Collaborative Innovation Center of Chemistry for Life Sciences, School of Life Sciences, Nanjing University, Nanjing, 210093, China. Electronic address: .
Xu Q; State Key Laboratory of Pharmaceutical Biotechnology and Collaborative Innovation Center of Chemistry for Life Sciences, School of Life Sciences, Nanjing University, Nanjing, 210093, China. Electronic address: .
Pokaż więcej
Źródło :
Journal of pharmacological sciences [J Pharmacol Sci] 2020 Nov; Vol. 144 (3), pp. 139-146. Date of Electronic Publication: 2020 Aug 03.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Phosphoric Monoester Hydrolases*/metabolism
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*genetics
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*physiology
Cerebrosides ; Depsipeptides ; Gain of Function Mutation ; Humans ; LEOPARD Syndrome/genetics ; Loss of Function Mutation ; Molecular Targeted Therapy ; Noonan Syndrome/genetics ; Piperidines ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/antagonists & inhibitors ; Pyrimidines ; Signal Transduction/genetics
Czasopismo naukowe
Tytuł :
Specific inhibition of SHP2 suppressed abdominal aortic aneurysm formation in mice by augmenting the immunosuppressive function of MDSCs.
Autorzy :
Lu Y; Clinical Laboratory, Hebei General Hospital, China.
Ma Q; Clinical Laboratory, Hebei General Hospital, China.
Tan H; Clinical Laboratory, Hebei General Hospital, China.
Li X; Clinical Laboratory, Hebei General Hospital, China.
Zhang X; Hebei North University, China.
Tie Y; Clinical Laboratory, Hebei General Hospital, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Jan 15; Vol. 265, pp. 118751. Date of Electronic Publication: 2020 Nov 12.
Typ publikacji :
Journal Article
MeSH Terms :
Aortic Aneurysm, Abdominal/*metabolism
Myeloid-Derived Suppressor Cells/*metabolism
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*antagonists & inhibitors
Angiotensin II/metabolism ; Angiotensin II/pharmacology ; Animals ; Aorta, Abdominal/metabolism ; Aorta, Abdominal/pathology ; Aortic Aneurysm, Abdominal/prevention & control ; Benzenesulfonates/pharmacology ; Disease Models, Animal ; Hydrazones/pharmacology ; Macrophages/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout, ApoE ; Myeloid-Derived Suppressor Cells/immunology ; Myeloid-Derived Suppressor Cells/pathology ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism ; Signal Transduction
Czasopismo naukowe
Tytuł :
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms.
Autorzy :
Wang Y; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Mohseni M; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Grauel A; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Diez JE; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Guan W; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Liang S; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Choi JE; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Pu M; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Chen D; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Laszewski T; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Schwartz S; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Gu J; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Mansur L; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, USA.
Burks T; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, USA.
Brodeur L; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Velazquez R; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Kovats S; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Pant B; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Buruzula G; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Deng E; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Chen JT; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Sari-Sarraf F; Analytical Sciences & Imaging, Novartis Institutes for BioMedical Research, Cambridge, USA.
Dornelas C; Analytical Sciences & Imaging, Novartis Institutes for BioMedical Research, Cambridge, USA.
Varadarajan M; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Yu H; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Liu C; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Lim J; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Hao HX; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Jiang X; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Malamas A; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
LaMarche MJ; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, USA.
Geyer FC; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
McLaughlin M; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Costa C; Oncology Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Wagner J; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Ruddy D; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Jayaraman P; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Kirkpatrick ND; Analytical Sciences & Imaging, Novartis Institutes for BioMedical Research, Cambridge, USA.
Zhang P; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Iartchouk O; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, USA.
Aardalen K; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Cremasco V; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Dranoff G; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Engelman JA; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Silver S; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Wang H; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Hastings WD; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA. .
Goldoni S; Oncology Disease Area, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2021 Jan 14; Vol. 11 (1), pp. 1399. Date of Electronic Publication: 2021 Jan 14.
Typ publikacji :
Journal Article
MeSH Terms :
Immunity, Cellular*
Neoplasm Proteins/*immunology
Neoplasms, Experimental/*immunology
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*immunology
Signal Transduction/*immunology
T-Lymphocytes/*immunology
Animals ; Cell Line, Tumor ; Gene Knockout Techniques ; HEK293 Cells ; Humans ; Mice ; Mice, Inbred BALB C ; Neoplasm Proteins/genetics ; Neoplasms, Experimental/genetics ; Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics ; Signal Transduction/genetics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies